224 related articles for article (PubMed ID: 31665212)
21. Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.
Ukleja A; To C; Alvarez A; Lara LF
JPEN J Parenter Enteral Nutr; 2018 May; 42(4):821-825. PubMed ID: 29603279
[TBL] [Abstract][Full Text] [Related]
22. New approaches to the treatments of short bowel syndrome-associated intestinal failure.
Jeppesen PB
Curr Opin Gastroenterol; 2014 Mar; 30(2):182-8. PubMed ID: 24406477
[TBL] [Abstract][Full Text] [Related]
23. Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.
Micic D; Robinson I; Kidd T; Terreri B; Raphael BP
Nutr Clin Pract; 2024 Jun; 39(3):634-640. PubMed ID: 38491966
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
Kocoshis SA; Merritt RJ; Hill S; Protheroe S; Carter BA; Horslen S; Hu S; Kaufman SS; Mercer DF; Pakarinen MP; Venick RS; Wales PW; Grimm AA
JPEN J Parenter Enteral Nutr; 2020 May; 44(4):621-631. PubMed ID: 31495952
[TBL] [Abstract][Full Text] [Related]
25. Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up.
Zaczek Z; Jurczak-Kobus P; Panczyk M; Braszczyńska-Sochacka J; Majewska K; Kunecki M; Dąbrowska K; Sobocki J
Nutrients; 2022 Apr; 14(8):. PubMed ID: 35458196
[TBL] [Abstract][Full Text] [Related]
26. The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.
Guz-Mark A; Hino B; Berkowitz D; Hartman C; Millman PN; Orlanski-Meyer E; Shaoul R; Spector-Cohen I; Weiss B; Zangen T; Shamir R
J Pediatr Gastroenterol Nutr; 2022 Sep; 75(3):293-298. PubMed ID: 35730756
[TBL] [Abstract][Full Text] [Related]
27. Gut hormones in the treatment of short-bowel syndrome and intestinal failure.
Jeppesen PB
Curr Opin Endocrinol Diabetes Obes; 2015 Feb; 22(1):14-20. PubMed ID: 25485516
[TBL] [Abstract][Full Text] [Related]
28. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
Yazbeck R
Curr Opin Mol Ther; 2010 Dec; 12(6):798-809. PubMed ID: 21154171
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 2 analogues in the treatment of intestinal failure: A qualitative exploration of the views of patients and their families in decision making.
Sowerbutts AM; Burden S; Griffiths J; Abraham A; Farrer K; Leahy G; Teubner A; Cloutier A; Twist K; Kelly S; Lal S
Clin Nutr ESPEN; 2021 Aug; 44():263-269. PubMed ID: 34330477
[TBL] [Abstract][Full Text] [Related]
30. Teduglutide for the treatment of short bowel syndrome - a safety evaluation.
Kochar B; Herfarth HH
Expert Opin Drug Saf; 2018 Jul; 17(7):733-739. PubMed ID: 29848084
[TBL] [Abstract][Full Text] [Related]
31. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
[TBL] [Abstract][Full Text] [Related]
32. Treatment of adult short bowel syndrome patients with teduglutide.
Nørholk LM; Holst JJ; Jeppesen PB
Expert Opin Pharmacother; 2012 Feb; 13(2):235-43. PubMed ID: 22224470
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
Jeppesen PB
JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report.
Borioli V; Cereda E; Lobascio F; Mengoli C; Caraccia M; Pagani A; Aronico N; Pedrazzoli P; Di Sabatino A; Caccialanza R
Nutrition; 2020 May; 73():110720. PubMed ID: 32088500
[TBL] [Abstract][Full Text] [Related]
35. Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.
Armstrong D; Forbes A; Jeppesen PB; Lee HM; Nagy P; Seidner DL
Clin Nutr; 2020 Jun; 39(6):1774-1777. PubMed ID: 31522784
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.
Lambe C; Talbotec C; Kapel N; Barbot-Trystram L; Brabant S; Nader EA; Pigneur B; Payen E; Goulet O
Am J Clin Nutr; 2023 Jun; 117(6):1152-1163. PubMed ID: 37270289
[TBL] [Abstract][Full Text] [Related]
37. [Review of real-life teduglutide experience].
Campos Martín C; Tejera Pérez C; Virgili-Casas N; Irles-Rocamora JA
Nutr Hosp; 2023 Aug; 40(4):886-894. PubMed ID: 37409717
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
Kochar B; Long MD; Shelton E; Young L; Farraye FA; Yajnik V; Herfarth H
J Clin Gastroenterol; 2017 Jul; 51(6):508-511. PubMed ID: 27433811
[TBL] [Abstract][Full Text] [Related]
39. A Treatment for Refractory High Ileostomy Output.
Semmens S; Higgins E; Coyne P
J Pain Palliat Care Pharmacother; 2018; 32(2-3):155-157. PubMed ID: 30395777
[TBL] [Abstract][Full Text] [Related]
40. Teduglutide in short bowel syndrome patients: A way back to normal life?
Harpain F; Schlager L; Hütterer E; Dawoud C; Kirchnawy S; Stift J; Krotka P; Stift A
JPEN J Parenter Enteral Nutr; 2022 Feb; 46(2):300-309. PubMed ID: 34614239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
